SCHEMBL2478734

SCHEMBL2478734

C=CCC(N)c1ccccc1-c1cnc2ccccc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.41
PDGFRA P16234 4/20 0.41
CYP2A6 P11509 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
BIRC5 O15392 1/20 0.39
PIK3CA P42336 2/20 0.38
PIK3CD O00329 1/20 0.38
PDCD1LG2 Q9BQ51 2/20 0.37
CD274 Q9NZQ7 2/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
PIM1 P11309 1/20 0.37
PIM3 Q86V86 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
NISCH Q9Y2I1 1/20 0.36
CYP1A2 P05177 1/20 0.36
MAP4K4 O95819 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480866 0.80 HDAC4 (0.42) PIK3CAPIK3CDPDCD1LG2CD274CYP1A2
Hydrochloric Acid SCHEMBL2480213 0.74 PDCD1LG2 (0.39) CYP2A6CA12CA1CA2CA9
SCHEMBL2476759 0.71 PRKCZ (0.42) PDCD1LG2CD274CYP1A2EGFR
SCHEMBL2474135 0.71 PDCD1LG2 (0.40) CA12CA1CA2CA9PDCD1LG2
SCHEMBL2471466 0.71 PTGS2 (0.38) PDGFRBCA12CA1CA2CA9
SCHEMBL7438146 0.71 PDCD1LG2 (0.40) CA12CA1CA2CA9PDCD1LG2
SCHEMBL2474509 0.70 TOP2A (0.42) PDCD1LG2CD274CYP1A2TOP2A
Hydrochloric Acid SCHEMBL2476183 0.70 ALOX5 (0.42) PDCD1LG2CD274CYP1A2
SCHEMBL23456217 0.70 ALDH1A1 (0.46) PDCD1LG2CD274CYP1A2
SCHEMBL2624503 0.70 PDGFRB (0.54) PDGFRBPDGFRACYP2A6CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159216-B1 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS ORGANON NV (NL) 2011-10-12 EP disclosed
EP-2159216-A1 Ih - Modulators N.V. Organon (NL) 2010-03-03 EP disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 PDGFRB 798/4885PDGFRA 1145/4885CYP2A6 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.